Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao'er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxia… Read more
Yipinhong Pharmaceutical Co Ltd Class A (300723) - Total Assets
Latest total assets as of September 2025: CN¥4.53 Billion CNY
Based on the latest financial reports, Yipinhong Pharmaceutical Co Ltd Class A (300723) holds total assets worth CN¥4.53 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Yipinhong Pharmaceutical Co Ltd Class A - Total Assets Trend (2013–2024)
This chart illustrates how Yipinhong Pharmaceutical Co Ltd Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Yipinhong Pharmaceutical Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Yipinhong Pharmaceutical Co Ltd Class A's total assets of CN¥4.53 Billion consist of 28.6% current assets and 71.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.7% |
| Accounts Receivable | CN¥362.34 Million | 8.2% |
| Inventory | CN¥287.13 Million | 6.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥441.17 Million | 10.0% |
| Goodwill | CN¥255.94K | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Yipinhong Pharmaceutical Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yipinhong Pharmaceutical Co Ltd Class A's current assets represent 28.6% of total assets in 2024, a decrease from 37.4% in 2013.
- Cash Position: Cash and equivalents constituted 10.7% of total assets in 2024, up from 7.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 22.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 10.0% of total assets.
Yipinhong Pharmaceutical Co Ltd Class A Competitors by Total Assets
Key competitors of Yipinhong Pharmaceutical Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Yipinhong Pharmaceutical Co Ltd Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Yipinhong Pharmaceutical Co Ltd Class A generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Yipinhong Pharmaceutical Co Ltd Class A is currently not profitable relative to its asset base.
Yipinhong Pharmaceutical Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.49 | 1.05 | 2.17 |
| Quick Ratio | 1.22 | 0.86 | 1.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥507.12 Million | CN¥ 70.04 Million | CN¥ 652.22 Million |
Yipinhong Pharmaceutical Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Yipinhong Pharmaceutical Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.26 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | CN¥4.40 Billion |
| Market Capitalization | $677.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Yipinhong Pharmaceutical Co Ltd Class A's assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Yipinhong Pharmaceutical Co Ltd Class A's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Yipinhong Pharmaceutical Co Ltd Class A (2013–2024)
The table below shows the annual total assets of Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.40 Billion | -0.03% |
| 2023-12-31 | CN¥4.41 Billion | +7.49% |
| 2022-12-31 | CN¥4.10 Billion | +10.64% |
| 2021-12-31 | CN¥3.70 Billion | +72.69% |
| 2020-12-31 | CN¥2.15 Billion | +19.52% |
| 2019-12-31 | CN¥1.79 Billion | +0.78% |
| 2018-12-31 | CN¥1.78 Billion | +20.18% |
| 2017-12-31 | CN¥1.48 Billion | +96.98% |
| 2016-12-31 | CN¥752.32 Million | +19.31% |
| 2015-12-31 | CN¥630.56 Million | -14.07% |
| 2014-12-31 | CN¥733.80 Million | +78.42% |
| 2013-12-31 | CN¥411.27 Million | -- |